Studying the BMPR2-activin pathway in pulmonary hypertension caused by left heart disease
Follows adults with heart failure to study how lung blood pressure rises.
Plain-language title generated from the registry record
Registry title: Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.
Key facts
- Where
- Madrid, SpainSee the site
Where in Spain
- Hospital GU Gregorio MarañónMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital General Universitario Gregorio Marañon
- Trial code
- NCT07537517
- Record updated
- 17 April 2026
- Original description
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.Read full original descriptionShow less
Evaluation of the BMPR2-Activin Signaling Pathway as a Key Mediator in Group II Pulmonary Hypertension. BREATHE-PH Study
Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.
Focusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.
Its aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.
We will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.
Clinical parameters, biomarkers, molecular profiles, and hemodynamic/echocardiographic variables will be analyzed.
A nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.
We will also assess reversibility of vascular remodeling one year after transplantation.
Results may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.
Inclusion: Older that 18 years; Heart failled patients with clinical indication for invasive hemodynamic assessment; Written consent.
Exclusion: Presence of iodinated contrast allergy; Refulsl to sign the infomred consent; Ineligibility for HT (for BREATHE-CT substudy).